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ABSTRACT- 
Transdermal drug delivery systems deliver thedrug through the skin at controlled rate to the systemic circulation. It 
maintains the blood concentration of the drug within the therapeutic system window ensuring that drug levels 
neither fall below the minimum effective concentration nor exceed theminimum toxic dose. The objective of the 
present work was to formulate transdermal gel of Lornoxicam. It is a COX-1 and COX-2 inhibitor used in the 
treatment of inflammation, pain and edema, rheumatoid arthritis. Transdermal gel of Lornoxicam was formulated 
using triethanolamine as solvent, HPMC K100 and EC as polymers. Formulated gel was evaluated with respect to 
different physiochemical parameters such as pH, viscosity, spreadability.  In-vitro release study was performed for 
10 hrs.  Selected formulation was subjected to stability testing at different temperatures.  
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INTRODUCTION 
Transdermal drug delivery system scuccessfully delivers preciseamount of drug through the skin for systemic 
action
1
. It has been accepted as potential non-invasive route of drug administration, with advantages of prolonged 
therapeutic effect, reduced side effects, improved bioavailability, better patient compliance and easy termination of 
drug therapy. Transdermal delivery offers a better route of delivery, it have better patient compliance by frequency 
of administration of the drug
2
. Skin is the outermost tissue of the human body. The skin basically consists of three 
anatomical layers epidermis, dermis, subcutaneous. For a drug penetrating across the skin the greatest resistance is 
met in the stratum corneum, viable epidermis and dermis
3
. 
The term ‘gel’ was introduced in the later 1800 to name some semisolid material according to 
pharmacological, rather than molecular criteria. Gels are transparent or translucent semisolid formulations and is 
colloid that is typically 99% weight liquid, which is immobilized by surface tension between it and a 
macromolecular network of fibers built from small amount of a gelating substances present. When dispersed in an 
appropriate solvent, gelling agents merge or entangle to form a three dimensional colloidal network structure, which 
limits fluid by entrapment and immobilization of the solvent molecules
4
. Transdermal application of gels at 
pathological sites offer great advantage in a faster release of drug directly to the site of action, independent of water 
solubility of drug as compared to creams and ointments
5
.
. 
Lornoxicam is a potent non-steroidal antiinflammatory 
drug, used for the variety of inflammatory conditions. The mechanism of action includes inhibition of prostaglandin 
synthesis through the inhibition of cyclooxygenase enzymes
6
. Lornoxicam is oneofthe newer and potent NSAIDs 
that inhibit the prostaglandin synthetase cyclo-oxygenase and act as useful antiinflammatory agent to control 
rheumatoid arthritis and other related conditions
7
,
8
. 
To avoid invasive drug therapy such as injections and to eliminate frequent dosing regimen with oral administration, 
a transdermal drug delivery system of Lornoxicam has been studied as an alternative dosage form. 
 
MATERIALS AND METHODS-  
Lornoxicam was obtained from Olex pharmaceuticals, Nigeria as gift sample. HPMC K100 wasobtained from 
Juneng Nigeria Ltd and ethyl cellulose from Neildek Trading company, Aba. All other chemicals were of analytical 
grade. 
Development of Lornoxicam transdermal gel: 
Different Lornoxicam transdermal gel formulations were prepared by adding differentingredients as shown in table 
1 by means of a magnetic stirrer with continuous mixing until a homogenous gel was formed. The solution was then 
neutralized and made viscous by addition of triethanolamine. Final weight was made up to 100 g with distilled 
water. The gel was set aside for few minutes until the bubbles disappeared. All the samples were allowed to 
equilibrate for at least 24 hours at room temperature prior to performing rheological measurements. The gels were 
kept in plastic well-closed containers and stored at room temperature until the time ofanalysis
9
.  
 
 
 
 
 
 
  
 
Table-1: Compositions of the Lornoxicam transdermal gel formulations 
S.N. Ingredients LTG1 LTG2 LTG3 LTG4 S.N. Ingredients LTG1 
1.  Lornoxicam 
(gms) 
0.06 0.06 0.06 0.06 2.  Lornoxicam 
(gms) 
0.06 
3.  HPMC K100 0.3 - 0.6 - 4.  HPMC K100 0.3 
5.  EC - 0.3 - 0.6 6.  EC - 
7.  Methyl Paraben 
(gms) 
0.75 0.75 0.75 0.75 8.  Methyl Paraben 
(gms) 
0.75 
9.  Triethanolamine 
(ml) 
0.3 0.3 0.3 0.3 10.  Triethanolamine 
(ml) 
0.3 
 
EVALUATION OF FORMULATIONS 
 Physical appearance and homogeneity
  
The physical appearance and homogeneity of the prepared Lornoxicamtransdermal gels were tested by visual 
observations after the gels have been set in the container. They were tested for their appearance and presence of any 
aggregates
10
. 
Clarity
 11 
The clarity of various formulations was determined by visual inspection under blackand white background and it 
was graded as follows; turbid: +, clear: ++, very clear (glassy): +++ . 
 Drug content
  
A specific quantity (100mg) of Lornoxicam transdermal gel of different formulations was taken and dissolved in 
100ml of phosphate buffer of pH 7.4. The volumetric flask containing gel solution was shaken for 2hr on 
mechanical shaker in order to get complete solubility of drug. This solution wasfiltered and estimated 
spectrophotometrically at 380 nm using phosphate buffer (pH 7.4) as blank
12
. 
Viscosity study
  
The viscosity of the Lornoxicam transdermal gel formulation was determined using a Ostwald viscometer. The gel 
formulations were placed in the sample holder of the viscometer and allowed to settle for 5 min and theviscosity 
measured at a rotating speed of 50 rpm at room temperature (25 - 27
o
C)
13
.  
Measurement of pH
  
The pH of various gel formulations was determined by using digital pH meter. One gram of Lornoxicam 
transdermal gel formulation was dissolved in 100 ml distilled water and stored for two hours. Themeasurement of 
pH of each formulation was done in triplicate and average values were calculated
14
. 
Extrudability
  
The extrusion of the gel from the tube is an important during its application and in patient acceptance. This study is 
useful in explaining whether the gel is removing from the collapsible tube during application in proper manner or 
not. Gels with high consistency may not extrude from the tube whereas, low viscous gels may flow quickly, and 
hence suitable consistency is required in order to extrude the gel from the tube. The formulationswere filled into 
collapsible  
aluminum tubes. The tubes were pressed to extrude the 0.5 cm ribbon of the gel in 10 second and the extrudability of 
formulations was checked
15
. 
More quantity extruded better was extrudability. The extrudability was then calculated by using the following 
formula:  
Extrudability= (Applied weight to extrude gel from tube (in gm) )/(Area (in cm2) 
 
In-vitro drug release 
The in vitro drug release from different Lornoxicam transdermal gel formulations was studied across cellophane 
membranes using modified Keshery Chien diffusion cell. The receptor compartment was filled with the mixture of 
phosphate buffer of pH 7.4 and polyethylene glycol 400 and maintained at 37±0.5
o
C with constant magnetic stirring. 
Accurately weighed quantity of gel was placed on the donor compartment. The samples (1ml) wascollected from the 
receptor compartment at predetermined time interval and replaced by equal volume of fresh receptor solution to 
maintain constant volume allowing sink condition throughout the experiment. The amounts of drug in the sample 
were assayed spectrometrically at 322 nm against appropriate blank
16
. 
Stability study
  
  
Stability studies carried out by storing the prepared transdermal gel of batch TG12 at various temperature conditions 
like refrigeration on (2-8
0
C) room temperature (25±0.5
0
C) and elevated temperature (45±0.5
0
C) for a period of 12 
weeks. Drug content and variation in the average vesicle diameter were periodically monitored. ICH (International 
Conference on Harmonisation) guidelines were followed
17
. 
Table-2: Properties of Lornoxicam transdermal gel formulations 
Formulation 
Code 
Homogeneity pH
a
 Viscosity
a
 % Drug 
Content
a
 
Extrudability 
(Centipoise) 
LTG1 +++ 6.77±0.33 3290.5±0.14 97.28±0.58 ++ 
LTG2 ++ 7.14±0.22 2176.5±0.42 98.54±0.74 + 
LTG3 + 6.93±0.15 3463.7±0.15 98.26±0.32 + 
LTG4 ++ 6.84±0.45 3468.4±0.45 98.72±0.47 ++ 
a  Average SD of three determination has been reported, +: Satisfactory, ++: Good, +++: Excellent 
 
 
 
Figure- 1: Percentage of drug released from Lornoxicam transdermal gel formulations 
 
 Figure-2: Stability study of Lornoxicam transdermal gel of batch LTG4 at different temperature 
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RESULTS AND DISCUSSION- 
Four transdermal gel formulations of Lornoxicamwere prepared by using different polymers i.e. HPMC, EC in 
different ratio.  
Stability of the transdermal gel is crucial both during storage and in-vivo application. The amount of drug retained 
within the vesicles under defined conditions ultimately governs the shelf life of the drug. The purpose of stability 
testing is to provide evidence on how the quality of a drug substance or drug product varies with time under 
influence of a variety of environmental factors such as temperature, humidity and light, andenables recommended 
storage conditions. 
Accelerated stability studies for 12 weeks revealed that the transdermal gel formulation werestable at up to 45
0
C. 
The results showed that transdermal gel formulation was quite stable at refrigeration and room temperatures as not 
much leakage of drug was found at these temperatures.  Therefore, the selected transdermal gel formulations can be 
stored at either refrigeration or room temperature. The pure drug shows sensitivity to light and moisture.  The 
physical appearance and homogeneity of the prepared Lornoxicam transdermal gels were tested by visual 
observations after the gels have been set in the container.  The drug content of the gel formulations shows content 
uniformity in all formulations. All transdermal gel formulations were found to be transparent and were free from 
presence of particles. There was good homogeneity in all formulations and no lumps were present. The pH of the gel 
formulations was in the range of 6.77 to 7.14, which lies in the normal pH range of the skin and would not produce 
any skin irritation. Viscosity of various formulated gels was found in the range of 2176.5 to 3468.4 centipoises. The 
extrudability of formulations was found to be satisfactory and good. The in-vitro permeation of Lornoxicam 
transdermal gels formulation was studied using locally fabricated Franz diffusion cell. The cumulative percent drug 
release after 10 hrs in between 50.3 to 82.11 %.  Rapid drug leakage was observed during the initial phase. 
However, after that a slow release occurred.  It was also observed that the drug release generally decreased as the 
polymer ratio increased. The release of the drug was retarded due to the hydrophobicand insoluble nature of the 
polymers used.  
 
CONCLUSION 
At present scenario transdermal application of gels at pathological sitesoffer great advantage in a faster release of 
drug directly to the site of action, independent of water solubility of drug as compared to creams and ointments.  
The present study has been a satisfactory attempt to formulate Lornoxicam transdermal gel formulations 
with a view of improving its oral bioavailability and giving a prolonged release of drug.  It has been 
observed that optimized batch produces the gel with good consistency, homogeneity, spreadibility. All 
transdermal gel formulations were found to be transparent and were free from presence of particles. 
The stability study of the optimized formulation showed satisfactory characteristics without being drastically 
influenced. On basis of drug content, particle size morphology, in-vitro release and stability studies, it can be 
concluded that formulation LTG4 was an optimum formulation. Howeverthere is need in-vivo study to 
justify the development of transdermal gel of Lornoxicam. 
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